Feedback and Inquiries.

Sam Mazin, Ph.D. and Akshay Nanduri founded RefleXion Medical in 2009.

Todd Powell assumed the roles of president and CEO in 2017 after a successful leadership tenure with Elekta, one of the industry’s largest manufacturers of radiotherapy systems. In 2018, Martyn Webster joined the team as CFO bringing specific expertise in medical device startups and fundraising. To date, the company employs more than 250 people, and is growing rapidly.

RefleXion has raised over $400M in financing from a top-tier investments.

The co-founders, Sam Mazin, Ph.D. and Akshay Nanduri have assembled an impressive internal team and advisory boards comprised of KOLs and renowned industry veterans. Todd Powell assumed the roles of president and CEO in 2017 after a successful leadership tenure with Elekta, one of the industry’s largest manufacturers of radiotherapy systems. In 2018, Martyn Webster joined the team as CFO bringing specific expertise in medical device startups and fundraising. To date, the company employs over 150 people, and is growing rapidly.

To reveal cancer as never before and beat it for everyone, everywhere.

To create a machine that combines biotargeting with radiation and enable the first-ever systemic reach for radiotherapy for patients with any stage of cancer.

SCINTIX biology-guided radiotherapy™ is the first to utilize the unique biology of the cancer itself to control radiotherapy delivery, even in tumors that are moving. The RefleXion® X1 machine with SCINTIX therapy is the first-ever platform that combines PET (positron-emission tomography) technology—the gold standard for cancer staging and imaging—with radiation therapy to track radiation dose delivery and potentially treat multiple tumors during daily treatment while sparing healthy tissue.

SCINTIX therapy is indicated for tumors in the lung or bone and is FDA cleared.

SCINTIX biology-guided radiotherapy is delivered through the RefleXion X1 machine, which combines positron emission tomography (PET) with a linear accelerator (LINAC) to deliver a radiation dose that tracks the cancer’s motion. Immediately prior to treatment, the patient is injected with a radiopharmaceutical that interacts with cancer cells to produce signals or emissions. The X1 continuously constructs a map from the detected emissions data that determines where to aim beamlets of radiation.

SCINTIX therapy is now commercially available for sale. Please contact your healthcare provider for availability.

Our unique name for biology-guided radiotherapy is a nod to our underlying scintillation technology that makes it all possible. The first part of the name “SCINTI” refers to our unique PET scintillation technology that captures the signals from the radiopharmaceuticals we use in real time to see the cancer. The last letter “X” refers to treating with X-rays or photons. So, taken together, the name is intended to denote “seeing” the disease combined with then treating it.

Yes. In addition to SCINTIX therapy, you can also deliver SBRT, SRS and IMRT to treat any solid indicated tumors throughout the body

The RefleXion X1 fits in most standard radiotherapy vaults with minimum shielding requirements to reduce the implementation timelines and startup costs.

Yes. The RefleXion X1 includes a premium couch top with indexing that allows for 3rd party immobilization devices.

Your contouring tools are compatible and the RefleXion X1 treatment planning system handles plan optimization and dose calculation.